The report also suggests that ataxia telangiectasia and Rad3-related protein inhibition could be a valuable tool to overcome resistance. A new analysis using CRISPR screens has revealed insights that ...
Hosted on MSN
Advanced Prostate Cancer Update: Adding PARP Inhibitor To Standard Of Care Can Notably Improve Outcomes
Patients with a type of prostate cancer known as metastatic castration-sensitive prostate cancer (mCSPC), who have specific genetic mutations, were found to have improved survival by using a targeted ...
A phase 2 trial will analyze the novel drug ART4215 with Talzenna, a PARP inhibitor, for patients with BRCA-deficient breast cancer. A phase 2 expansion study is now underway, examining the novel drug ...
Most recurrent ovarian cancer cases arise in patients previously treated with PARP inhibitors making these results noteworthy ...
Niraparib combined with abiraterone acetate and prednisone improved rPFS in mCSPC patients with HRR gene alterations, especially BRCA1/2 mutations. The combination showed potential in reducing ...
Cybrexa Therapeutics, a biotechnology company developing a new class of cancer therapeutics through its alphalex™ tumor targeting platform, today announced that the FDA- and EMA-approved poly ...
TAMPA, Fla. — Ovarian cancer, often diagnosed at an advanced stage, presents significant treatment challenges because patients tend to develop resistance to conventional therapies quickly. Despite ...
NEW ORLEANS -- A triplet combination of the PARP inhibitor olaparib (Lynparza), metronomic cyclophosphamide, and metformin was feasible and showed encouraging efficacy in elderly, heavily pretreated ...
Some anti-cancer treatments not only target tumor cells but also healthy cells. If their effects on the latter are too strong, their use can become limiting. A team from the University of Geneva ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback